NCT07090954
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Not Yet Recruiting · Phase 1, Phase 2 · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · registry updated 2025-07-29
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
Inclusion
- Eastern Cooperative Oncology Group performance status grade of 0, 1 or 2;
- Diagnosis of multiple myeloma；have received at least one prior line of therapy including Lenalidomide and a proteasome inhibitor.
- Able to understand and comply with the requirements of the clinical protocol, voluntarily participate in the clinical trial, and sign informed consent.
Exclusion
- Plasma cell leukemia , Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis.
- Active central nervous system involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
- Prior treatment with any BCMA-targeted therapiy.
- Active infecion.
- Known allergies, hypersensitivity, or intolerance to the study drug or its excipients.